Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000899428 | SCV001043694 | benign | Mucopolysaccharidosis, MPS-II | 2024-01-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002363345 | SCV002664776 | likely benign | Inborn genetic diseases | 2018-02-14 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV000899428 | SCV005089179 | likely pathogenic | Mucopolysaccharidosis, MPS-II | 2024-06-07 | criteria provided, single submitter | literature only | Absent from controls (or at low frequency) in gnomAD database (PM2_Moderate), Patient’s phenotype or family history highly specific for the disease (PP4_Strong) |
Natera, |
RCV001825812 | SCV002084485 | likely benign | Mucopolysaccharidosis, MPS-III-A | 2021-02-05 | no assertion criteria provided | clinical testing |